The New England journal of medicine
-
Randomized Controlled Trial Multicenter Study Comparative Study
Omadacycline for Community-Acquired Bacterial Pneumonia.
Omadacycline, a new once-daily aminomethylcycline antibiotic agent that can be administered intravenously or orally, reaches high concentrations in pulmonary tissues and is active against common pathogens that cause community-acquired bacterial pneumonia. ⋯ Omadacycline was noninferior to moxifloxacin for the treatment of community-acquired bacterial pneumonia in adults. (Funded by Paratek Pharmaceuticals; OPTIC ClinicalTrials.gov number, NCT02531438 .).
-
Randomized Controlled Trial Multicenter Study Comparative Study
Omadacycline for Acute Bacterial Skin and Skin-Structure Infections.
Acute bacterial skin and skin-structure infections are associated with substantial morbidity and health care costs. Omadacycline, an aminomethylcycline antibiotic that can be administered once daily either orally or intravenously, is active against pathogens that commonly cause such infections, including antibiotic-resistant strains. ⋯ Omadacycline was noninferior to linezolid for the treatment of acute bacterial skin and skin-structure infections and had a similar safety profile. (Funded by Paratek Pharmaceuticals; OASIS-1 ClinicalTrials.gov number, NCT02378480 .).
-
Editorial Comment
PIONEERing the In-Hospital Initiation of Sacubitril-Valsartan.